VN February 2026

Vetnuus | February 2026 25 Curiously, we found that all animals remained anti-NSP antibody negative following vaccination except for two heifers from the twodose A24-P2/P3Deopt 104 pfu dose group. By 14 dpc, all animals from the control, two-dose 104 and one-dose 105 A24-P2/P3Deopt dose groups were anti-NSP antibody positive, while 3/4 heifers were positive from the remaining two-dose 105 and 106 dose groups. The results at 0 dpc again cast doubt on the DIVA compliance of this vaccine candidate as formulated and with the current available tests, and indicate that further tweaking of the sequence may be necessary for true DIVA compliance. Finally, we were interested in assessing the broadly neutralising capacity of the antibodies elicited by animals inoculated with the LAV candidate. To that end, we tested the sera of two-dose 105 and 106 pfu A24-P2/P3Deopt inoculated cattle from 0, 7, 14 and 21 dpi against six other serotype A strains, and two different serotype strains, Asia1 and O1Manisa (Fig 8A) and used the resulting titers to calculate the r1 value (defined as the quotient of the titer against the heterologous strain over the titer against the homologous strain) for each strain. In general, sera from the two-dose 105 pfu dose group consistently performed as well or better than samples from the two-dose 106 pfu dose group against a variety of serotype A strains, both in the aggregate and over time. Titers continued to rise or remain steady up to 21 dpi in all A strains except A12, where a slight decline in average titer was observed at 21 dpi, though the titer and r1 value continue to exceed the threshold for protection. In contrast, the sera from the two-dose 106 pfu A24-P2/ P3Deopt inoculated cattle showed a decline in neutralising capacity by 14 dpi (A22 Iraq and A Iran) or by 21 dpi (A27) in three of six A strains tested. Additionally, when tested against A79, sera from the two-dose 106 pfu A24-P2/P3Deopt inoculated animals took longer to achieve an average protective r1 value of 0.3 (14 dpi vs 7 dpi) than the twodose 105 pfu A24-P2/P3Deopt dose group. While no titer was obtained against O1Manisa at any timepoint (data not shown), the sera of the two-dose 105 pfu dose group reached a neutralising titer as well as an R1 value greater than 0.3 against serotype Asia1 by 7 dpi, though the titer returned to 0 by 21 dpi. Phylogenetic analysis of VP1 (Fig 8B, S1 Fig) from the strains used for the cross-protection neutralisation assay reveals low correlation with the r1 values obtained by this assay. However, while r1 values remained strong over the various timepoints tested (7, 14 and 21 dpi) for all serotype A strains, particularly among the A24-P2/P3Deopt 105 pfu dose group, r1 values fell to just above zero by 21 dpi for the more distantly related Asia1 strain. DISCUSSION Our work demonstrates that the A24-P2/P3Deopt strain is a highly effective live attenuated vaccine candidate with a broad safety margin and ability to elicit a strong, cross-protective neutralising antibody response when administered in cattle, improving current vaccine strategies. Specifically, we have demonstrated that A24-P2/P3Deopt is safe at IDL doses as high as 107 pfu and effective at a prime-boost dose of 104 pfu, establishing a safety margin in cattle of at least three logs. LAVs are generally understood to be the most successful type of vaccine, not only because they typically induce stronger protection, but also because they bring other advantageous qualities that make them easier to deploy than other vaccine types commonly applied to viral illnesses. For example, all commercial LAVs—with the exception of the oral polio vaccine—are lyophilised, a process of freeze-drying that results in significantly improved stability, sterility of the end-product and reduced reliance on cold chain 28. This reduced reliance on cold chain also significantly reduces the cost of producing these vaccines and improves their distribution to remote and low-resource areas for field application. In addition to cost savings from reduced cold chain reliance, LAVs also require less viral material per dose. For example, the commercially available FMD vaccine formulation is administered at 10 µg/dose, an amount equivalent to about 2 × 10^8 pfu (using FMDV A12 for demonstrative purposes, which has a molar mass of 8.6 × 10^6 g/mol and a viral particle-to-pfu ratio of 5000 VP/pfu 21). By comparison, while the viral particle-to-pfu ratio of the present A24-P2/P3Deopt LAV is 27,000 VP/pfu, at the lowest effective dose schedule investigated—two doses at 1x104 pfu each—the viral material administered in a commercially inactivated vaccine is still 3 logs higher than for A24-P2/P3Deopt. Production cost of codon deoptimized FMD vaccines could also be further reduced if the CD strain were delisted on the United States Select Agent Program regulations and able to be grown outside of BSL-3 facilities, as has happened for other FMD attenuated vaccine strains such as FMDV A24 Leaderless 29. Another benefit of LAVs is their ability to confer early, long-lasting and broad-spectrum immunity by recruiting both humoral and cellular arms of the immune system. In the past, while several attenuated strains tested in cattle were not capable of inducing protective levels of immunity, swine inoculated with FMDV SAP mutant were protected against WT homologous challenge as early as 2 days after inoculation 30. In the present study, animals inoculated with the highest dose in the efficacy study (106 pfu), showed systemic protective antibody titer by 4 dpi, at least as rapidly as the adjuvanted inactivated FMD vaccine formulation 5, suggesting the present LAV vaccine could be an effective substitute and may be protective even at this early time point, though a challenge study should be conducted to confirm this hypothesis. While the precise mechanisms of attenuation conferred by CD or CPD are not well-understood, particularly in the context of FMDV, many well-supported hypotheses exist. First, CPD has been shown to increase CpG and UpA dinucleotide frequencies in the resulting viruses (as reviewed in 31). These dinucleotide pairs are far less frequent in mammalian hosts, and many innate immune-sensing molecules exist that target them, triggering an antiviral response that slows virus growth and spread among cells. Additionally, the increase in these uncommon dinucleotide pairs is attended by increasing frequency of “near-stop” codons, which are more prone to random mutation into stop codons, leading to evolutionary dead-ends. It has been long established that tRNA concentrations for uncommon codons tend to be lower, which may contribute to a reduced rate of translation 32. CPD is also understood to have effects on RNA secondary structure folding, which can result in changes in translation initiation and stalling and can further lead to misfolding of the amino acid chain (as reviewed in 33). All these putative mechanisms of attenuation result in viruses that are slow growing, which presents a drawback for large-scale production. Given the slower growth rate, CPD viruses are more time and resource-intensive than WT viruses. However, the cell lines used in virus propagation could be modified to make them more permissive to the replication of these CPD viruses with reduced fitness. For instance, the host factor variously known as zinc-finger antiviral protein (ZAP) and poly(ADP-ribose) polymerase 13 (PARP13), among others, is a viral nucleic acid sensor and a component of the innate immune system. ZAP targets and binds CpG dinucleotides in RNA and targets them for destruction 34. In the future, cell lines with knock-outs or RNA-binding domain mutations in antiviral proteins such as ZAP could be developed to improve CPD vaccine strain production. On the other hand, CD viruses showed a reduced translation efficiency because rare tRNAs are limiting, causing the ribosome to stall or pause, ultimately reducing protein yield and therefore influencing viral fitness 18,1935. CD also affects viral protein folding kinetics due to slowed translation 36. Therefore, both methods of deoptimization ultimately cause viral attenuation. In the present study, we observed a lack of detectable circulating virus by virus isolation and only low levels by PCR in some cattle, consistent with our previous findings in swine 23. Article >>>26

RkJQdWJsaXNoZXIy OTc5MDU=